The overall goal of the Transgenic/Knockout Rodent Core offers state-of-the-art services for the manipulation of mouse and rat genomes, ensuring that the primary beneficiaries of CCSG-supported Shared Resources have the best information and technical resources available to support cancer research. The Core, which is Cancer Center managed, was established in 1993 to produce transgenic and knockout mice for USC Norris members and to increase the use of mouse technology through education and consultation to the cancer research community. Since its inception, the Core has operated under the same faculty leader, Dr. Robert Maxson, and manager, Dr. Nancy Wu; it has also been continuously funded by the CCSG. The Core is widely recognized within the USC community and beyond for the high quality of its services. The Core produces transgenic and knockout mice and offers two important new services, knockout rats and CRISPR/Cas9- mediated gene editing in mice. Using ES cell technology pioneered by Dr. Qi-Long Ying at USC, the Core generated the first knockout rats. The new CRISPR/Cas9 technology will make it possible to produce gene knockouts much faster and at lower cost than current ES cell-based technology. The Core continues to be active in education and consulting services, and provides a number of important ancillary services, including in vitro fertilization, and re-derivation of mouse strains, as well as cryopreservation of embryos. At the last CCSG renewal, the Core received a merit rating of ?excellent? with reviewers noting the competence of the Core leadership and the high quality of the work. The only criticism was low usage by Cancer Center members, although it was recognized that the Core serves the entire USC community. We have stepped up efforts to promote the availability of the Core and encourage cancer investigators to use Core services in their research. In the most recent year, 12 peer-review funded members, or 71% of total users, from four Research Programs (Epigenetics and Regulation, Gastrointestinal Cancers, Molecular Genetics, and Tumor Microenvironment) used the Core to accomplish their research objectives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-44
Application #
9607928
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2018-12-01
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Battaglin, Francesca; Naseem, Madiha; Puccini, Alberto et al. (2018) Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int 18:99
Zhang, Junjie; Zhao, Jun; Xu, Simin et al. (2018) Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral Replication. Cell Host Microbe 24:234-248.e5
Eriguchi, Yoshihiro; Nakamura, Kiminori; Yokoi, Yuki et al. (2018) Essential role of IFN-? in T cell-associated intestinal inflammation. JCI Insight 3:
Thomas, Nancy E; Edmiston, Sharon N; Orlow, Irene et al. (2018) Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol 138:2398-2404
Cobo, Eduardo R; Holani, Ravi; Moreau, France et al. (2018) Entamoeba histolytica Alters ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency. Infect Immun :
Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu et al. (2018) Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer 17:e395-e414
Hanna, Diana L; Loupakis, Fotios; Yang, Dongyun et al. (2018) Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer 17:e471-e488
Rhie, Suhn Kyong; Yao, Lijun; Luo, Zhifei et al. (2018) ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream of transcription start sites at the majority of CpG island promoters. Genome Res :
Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194

Showing the most recent 10 out of 842 publications